FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Hikma Pharmaceuticals Sodium Chloride Injection Recall

Sodium Chloride Injection, USP, 0

Hikma Pharmaceuticals USA Inc. · Cherry Hill, NJ

Risk level
Class II
Reported by FDA
Nov 25, 2020
Recall ID
D-0101-2021
Check your lot numberHow we source this data

Summary

Hikma Pharmaceuticals recalled Sodium Chloride Injection starting Nov 3, 2020. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0101-2021 on Nov 25, 2020. Reason: Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial. Status: Terminated.

Why it was recalled

Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial.

Product description

Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/mL, 2mL Single Dose Vial, Preservative Free, For use as a sterile diluent, Rx Only, Mfd. by. West-ward Eatontown, NJ 07724 USA, a) Vial NDC 0641-0497-17, b) Carton of 25 vials NDC 0641-0497-25.

Lot numbers, UPCs & expiration codes

a) Vial Lot #s: 078338 Exp. 7/2021; Lot 088391, Exp. 08/2021; 098340, Exp. 09/2021; 108325 Exp. 10/2021; 010018 Exp. 1/2023; b) Carton Lot #: 068322, Exp. 06/2021.

Where it was sold

Nationwide in the U.S.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0101-2021
Classification
Class II
Status
Terminated
Recall initiated
Nov 3, 2020
FDA report date
Nov 25, 2020
Quantity
2,100,646 Vials
Recall type
Voluntary: Firm initiated
Recalling firm
Hikma Pharmaceuticals USA Inc.

Original FDA data

Every field from FDA enforcement report D-0101-2021, exactly as published.

Show all FDA fields
City
Cherry Hill
State
NJ
Status
Terminated
Country
United States
Event ID
86685
Address
2 Esterbrook Ln
Code information
a) Vial Lot #s: 078338 Exp. 7/2021; Lot 088391, Exp. 08/2021; 098340, Exp. 09/2021; 108325 Exp. 10/2021; 010018 Exp. 1/2023; b) Carton Lot #: 068322, Exp. 06/2021.
Postal code
08003-4002
Report date
Nov 25, 2020
Product type
Drugs
Recall number
D-0101-2021
Classification
Class II
Recalling firm
Hikma Pharmaceuticals USA Inc.
Product quantity
2,100,646 Vials
Termination date
Nov 17, 2022
Reason for recall
Failed pH Specifications: Out of Specification pH Test Results were found in Sodium Chloride Injection USP 0.9% 2 mL vial.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/mL, 2mL Single Dose Vial, Preservative Free, For use as a sterile diluent, Rx Only, Mfd. by. West-ward Eatontown, NJ 07724 USA, a) Vial NDC 0641-0497-17, b) Carton of 25 vials NDC 0641-0497-25.
Distribution pattern
Nationwide in the U.S.
Recall initiation date
Nov 3, 2020
Initial firm notification
Letter
Center classification date
Nov 20, 2020

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0101-2021, published Nov 25, 2020. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls